A carregar...
Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction
A 62-year-old female patient with renal dysfunction and pulmonary adenocarcinoma developed postoperative recurrence and received carboplatin/pemetrexed and maintenance pemetrexed. As an anaplastic lymphoma kinase (ALK) gene translocation was identified, the therapy was changed to crizotinib. However...
Na minha lista:
Publicado no: | Onco Targets Ther |
---|---|
Main Authors: | , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Dove Medical Press
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5499859/ https://ncbi.nlm.nih.gov/pubmed/28721071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S136837 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|